Esperion Therapeutics (ESPR) Operating Leases (2019 - 2026)
Esperion Therapeutics (ESPR) posted Operating Leases of $861000.0 for Q1 2026, up 31.85% on a QoQ basis from $653000.0 in Q4 2025, and down 56.34% year-over-year from $2.0 million in Q1 2025.
Esperion Therapeutics (ESPR) Operating Leases (2019 - 2026) Analysis & Trends
Esperion Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $861000.0 for Q1 2026.
- Quarterly Operating Leases fell 56.34% year-over-year to $861000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $861000.0 (down 56.34% YoY) and the FY2025 annual result came in at $653000.0, down 87.7% from the prior year.
- Operating Leases was $861000.0 for Q1 2026 at Esperion Therapeutics, up from $653000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $5.3 million in Q4 2024 and bottomed at $47000.0 in Q3 2022.
- A 5-year average of $1.8 million and a median of $1.3 million in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases slumped 96.42% — and 2023, when it jumped 4259.57%.
- Esperion Therapeutics' Operating Leases stood at $665000.0 in 2022, then jumped by 354.14% to $3.0 million in 2023, then soared by 75.86% to $5.3 million in 2024, then tumbled by 87.7% to $653000.0 in 2025, then soared by 31.85% to $861000.0 in 2026.
- Business Quant data shows ESPR's Operating Leases at $861000.0 in Q1 2026, $653000.0 in Q4 2025, and $767000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 861,000.00 |
| Dec 31, 2025 | 653,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 3.02 Mn |
| Sep 30, 2023 | 2.05 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 782,000.00 |
| Dec 31, 2022 | 665,000.00 |
| Sep 30, 2022 | 47,000.00 |
| Jun 30, 2022 | 135,000.00 |
| Mar 31, 2022 | 263,000.00 |
| Dec 31, 2021 | 524,000.00 |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.92 Mn |